Controversy exists regarding whether to place a plastic or a metal endobiliary stent in patients with resectable pancreatic cancer who require biliary drainage. Although self-expandable metal stents (SEMS) provide better drainage compared with plastic stents, concerns remain that SEMS may compromise resection and increase postoperative complications. Our objective was to compare surgical outcomes of patients undergoing pancreaticoduodenectomy (PD) with SEMS in place vs. plastic endoscopic stents (PES) and no stents (NS).
INTRODUCTION
Biliary obstruction is a frequent problem in patients with pancreatic cancer awaiting pancreaticoduodenectomy (PD). A recent well-publicized study showed that routine biliary drainage before PD is not indicated and associated with increased complications ( 1 ) . However, if the bilirubin is markedly elevated, the patient is symptomatic, or surgery needs to be delayed to optimize medical comorbidities or to administer neoadjuvant therapy, preoperative biliary drainage may still be required.
In patients with unresectable pancreatic cancer, self-expandable metal stents (SEMS) have become the preferred method of biliary drainage as they provide more durable patency, lower incidence of cholangitis, and are cost eff ective when compared with plastic endoscopic stents (PES) ( 2 -4 ) . However, in patients awaiting PD, traditional practice has been to place a PES because of concerns that SEMS may interfere with resection resulting in more operative complications and compromise of clear surgical margins (R0 resection). With recent studies showing promising outcomes with the use of neoadjuvant therapy, delay in PD for neoadjuvant treatment is becoming more common ( 5 ) . PES may not provide adequate patency in patients receiving neoadjuvant therapy, resulting in interruptions of treatments and further delay of surgery ( 6 ) . Routine use of PES in patients awaiting PD has recently been challenged, and several small studies have shown that SEMS do not result in increased operative and postoperative complications ( 7 -11 ) . Th e aim of our study was to compare surgical outcomes of a large group of patients undergoing attempted PD with SEMS in place vs. PES and no stents (NS).
METHODS
We retrospectively reviewed a prospectively maintained database that included all patients who underwent attempted or successful PD at Memorial Sloan-Kettering Cancer Center between March 2008 and July 2011. From this database, we extracted patient demographics, presence of a biliary stent at the time of surgery, operative details, perioperative complications, and pathology including tumor characteristics and margin status. Each perioperative complication was graded on a previously validated severity scale from 1 to 5 as described in Table 1 ( 12 ) . Patients were included if they were 18 years old and underwent successful PD, or deemed locally unresectable intraoperatively. Excluded were those with percutaneous biliary drainage and those deemed unresectable intraoperatively because of metastatic disease.
Electronic medical records were reviewed to determine the type of biliary stent in place at the time of operation and to assess comorbidities. Th e overall level of comorbid diseases was determined by the documented preoperative ASA (American Society of Anesthesiologists) physical status classifi cation. In those who were deemed unresectable at the time of surgery, medical records were reviewed to determine the cause.
All operations were performed by an experienced pancreatic surgeon on faculty at Memorial Sloan-Kettering Cancer Center. Preoperatively, each case and pertinent radiology was reviewed at a multidisciplinary conference to determine resectability. All fi nal pathology was reviewed and confi rmed. Th is study was approved by the institutional review board at Memorial Sloan-Kettering Cancer Center.
Variables were summarized for each stent type group using median and range for continuous variables and frequency and percent for categorical covariates. Diff erences across the three stent type groups (SEMS, PES, and NS) and between the SEMS and PES groups were assessed using Fisher ' s exact test (for categorical covariates) and analysis of variance (for continuous covariates). Length of stay and estimated blood loss were log-transformed for the analysis of variance to increase normality and two patients with estimated blood loss of 0 ml were assigned to 10 ml to allow transformation. A sensitivity analysis was performed using the Kruskal -Wallis test on untransformed EBL values and results were similar. Unresectability rates were summarized for the three stent type groups and Fisher ' s exact test was used to compare the unresectability rate in the SEMS group to the rate in each of the other groups.
Multivariate logistic regression models were used to assess the eff ect of stent type on complications, serious complications, and R0 resection aft er adjusting for other important covariates. Within the subset of patients with adenocarcinoma, a multivariate regression model adjusted for age, ASA class, and neoadjuvant chemotherapy was used to assess the association between stent type and unresectability.
RESULTS
A total of 593 patients who underwent either successful or attempted PD were identifi ed and reviewed. Of these, 84 were deemed unresectable intraoperatively and 509 underwent successful PD. Among the 509 who had successful PD, 71 patients had SEMS, 149 had PES, and 289 had NS.
Demographic data including age, gender, ASA class, diagnosis of adenocarcinoma, and use of neoadjuvant therapy in those who had undergone PD are listed in Table 2 . Th ere were no statistically signifi cant diff erences in gender between the three groups. Th e preoperative ASA class was higher, class 3 or 4, in the SEMS group compared with the PES group ( P = 0.029). Patients with either SEMS or PES tended to be older than the NS group ( P = 0.038). In the SEMS group, 67 (94.4 % ) had adenocarcinoma as compared with 145 (50.2 % ) in the NS group ( P < 0.001). Th ere was no statistically signifi cant diff erence in the rate of adenocarcinoma between the SEMS and PES groups (94.4 % in the SEMS group vs. 90.6 % in the PES group, P = 0.436). Th e pathology of those without adenocarcinoma primarily included other neoplasms including carcinoid, neuroendocrine tumors, sarcoma, intraductal papillary mucinous neoplasm, and benign fi ndings such as cystic disease and pancreatitis. Among patients with adenocarcinoma, 23 (34.3 % ) in the SEMS group received neoadjuvant therapy as compared with 10 (7.4 % ) in the PES group and 14 (9.7 % ) in the NS group ( P < 0.001).
Comparisons of operative and perioperative outcomes including length of stay, operative duration, estimated blood loss, any complication, serious (grade 3 -5) complication, biliary anastomotic leak, pancreatic anastomotic leak, wound infection, 30-day mortality, and positive margin on pathology are listed in Table 3 . No diff erences were found among all three groups with regard to length of stay, overall complications, and serious (grade 3 -5) complications. A positive margin based on fi nal pathology occurred in 6 patients (8.5 % ) in the SEMS group, 24 patients (16.3 % ) in the PES group, and 29 patients (10.2 % ) in the NS group ( P = 0.129). Postoperative wound infection rates diff ered by stent type ( P < 0.001) with PES P = 0.003) and 18 patients (6.2 % ) in the NS group. Th ere was a small yet statistically signifi cant diff erence in operative times between the SEMS group (median 279 min) as compared with the PES group (median 253 min, P = 0.03). Median operative time was 241 min in the NS group, and the diff erence across the three groups was signifi cant ( P < 0.001). Additionally, there was a small increase in estimated blood loss in the SEMS and PES groups compared with the NS group (median loss of 500 ml in both the SEMS and PES groups vs. 400 ml in the NS group; P = 0.028). Regarding SEMS, all except one case were of 10 mm diameter. Among the SEMS, 25 were covered, 44 were uncovered, and 2 cases were missing data. Th ere were no diff erences in complications, which occurred in 15 patients (60 % ) with covered stents compared with 29 (66 % ) with uncovered stents ( P = 0.794), and no diff erence in serious (grade 3 -5) complications, which occurred in 3 patients (12 % ) with covered stents vs. 9 (20 % ) in uncovered stents ( P = 0.515). With regard to stent length, 20 were 40 mm in length, 47 were 60 mm in length, 2 were 80 mm in length, and 4 cases were missing data. Again, there were no diff erences with regard to overall complications among the three groups, which occurred in 13 (65 % ) of the 40 mm length stents, 30 (64 % ) of the 60 mm stents, and 1 (50 % ) of the 80 mm stent ( P = 1.00). Additionally, there were no diff erences in serious (grade 3 -5) complications that occurred in 3 (15 % ) of the 40 mm length, 9 (19 % ) of the 60 mm length, and 0 of the 80 mm length ( P = 1.00). Table 4 shows the rates of local unresectability by stent type. Of the 84 patients who were deemed locally unresectable intraoperatively, 17 had SEMS in place at the time of surgery, 32 had PES, and 35 had NS. Th e rate of an intraoperative fi nding of locally unresectable disease was greater in the SEMS group (19.3 % ) compared with the NS group (10.8 % , P = 0.045), but similar compared with the PES group (17.7 % , P = 0.7391). However, of those with adenocarcinoma, there were no diff erences in unresectability rates among the three groups, which occurred in 19.3 % in the SEMS group as compared with 17.5 % in the NS group (SEMS vs. NS P = 0.732) and 17.7 % in the PES group (SEMS vs. PES P = 0.862). Addition- In a multivariate regression model, SEMS had overall more postoperative complications than the NS group when adjusting for ASA class, age, diagnosis of adenocarcinoma, and neoadjuvant therapy ( Table 5 ). However , there were no diff erences in serious (grade 3 -5) complications ( Table 6 ). Th ere were no signifi cant differences in either overall complications or serious complications between SEMS and PES when adjusting for the same covariates. ASA class had signifi cantly aff ected the risk of any complications as well as serious complications, and benign pathology was associated with an increased risk of any complication; no other covariate was signifi cantly associated with these outcomes ( Tables 5 and 6 ) . A multivariate regression model of the eff ect of stent type on the presence of a positive margin showed no diff erence between SEMS, NS, or PES on R0 resection when adjusting for ASA class, age, and neoadjuvant therapy ( P = 0.115).
DISCUSSION
Among patients who are undergoing a PD and who require endoscopic preoperative biliary drainage, this study found that the use of preoperative SEMS did not compromise R0 resection or increase overall or serious postoperative complications. Th ese fi ndings were observed in both univariate and multivariate analyses. Additionally, there were no diff erences in the rates of an intraoperative fi nding of locally unresectable disease (nontherapeutic laparotomy) among the three groups in patients with pancreatic adenocarcinoma. We did observe an increase in postoperative wound infections and longer operative times in the SEMS group, as well as more overall complications in the SEMS group as compared with the NS group in the multivariate analysis.
Routine preoperative biliary drainage in patients with pancreatic cancer undergoing PD has not been found to be benefi cial. Several retrospective studies have associated preoperative biliary drainage with increased postoperative complications, including studies from our own institution showing higher rates of infectious complications, including postoperative wound infections ( 13 -15 ) . In a recent randomized controlled trial, preoperative biliary drainage was compared with early PD alone, and showed an overall increase in complications in the stent group, primarily attributed to cholangitis, stent dysfunction, and need for repeated stent exchange ( 1 ) .
Although it has become generally accepted that routine biliary stenting before PD is not indicated, many patients still require biliary drainage while awaiting surgical resection, including those needing delay PD to correct comorbidities, those symptomatic Only patients with adenocarcinoma were eligible for neoadjuvant therapy. Only patients with adenocarcinoma were eligible for neoadjuvant therapy.
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chemotherapy, which may have contributed to the diff erences in wound infection. Additionally, as neoadjuvant chemotherapy is generally reserved at our institution for those with borderline resectable or locally unresectable tumors, it is not surprising that longer operative times were encountered in this group. Although there was a statistically signifi cant diff erence in estimated blood loss, the diff erence was quite small, and there was no diff erence seen between the stent types.
In comparing the patients who were deemed locally unresectable intraoperatively, although there was a signifi cant diff erence in unresectability rates between the SEMS and NS group for all patients, there was no diff erence seen when the subgroup of patients with adenocarcinoma were analyzed. Th ese fi ndings persisted in a multivariate regression model.
Lastly, there were no diff erences in overall or serious complications when comparing the diff erent SEMS types. Although there were no diff erences in complications between stent length, we recommend choosing the shortest length required to bridge the obstruction while leaving enough common hepatic duct for the biliary anastomosis.
Th e limitations of this study include the retrospective design resulting in the inability to equalize patient demographics, and a relatively small number of patients who received SEMS. However, to our knowledge, this is the largest group of SEMS investigated in a comparative study. Another limitation is that our patient population did not exclusively have pancreatic adenocarcinoma; however, the majority of nonadenocarcinoma patients were in the NS group, which we expect to be healthier and have lower risk of perioperative complications. Rates were nonetheless similar between NS and SEMS for most types of complications, indicating that SEMS did not lead to increased risk.
In conclusion, once the decision has been made to place a biliary stent in a patient with pancreatic cancer awaiting PD, a SEMS can be placed without the risk of increased overall or serious perioperative complications, risk of unresectability, or compromise R0 resection. Although our study shows that SEMS result in longer operative times and increase postoperative wound infections, we feel that the advantages of SEMS outweigh these potential risks. Based on our results, there is no contraindication to placing SEMS in the common bile duct of patients anticipating PD.
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It is well established that SEMS are superior to PES with regard to patency. Multiple studies in patients with unresectable pancreatic cancer comparing SEMS with PES have shown that SEMS have better patency profi les, with fewer incidences of cholangitis, stent occlusion, and need for reintervention ( 2, 3, 16 ) . More recent studies have shown similar patency advantages of SEMS in patients awaiting PD ( 7, 8, 11, 17 ) . In particular, as more patients are undergoing neoadjuvant therapy, PES do not provide adequate stent patency, resulting in interruptions of neoadjuvant treatments, need for hospitalizations, and repeated endoscopic procedures ( 6 ) . Th is has led to critique of the previous studies that concluded increased complications in patients who underwent preoperative biliary drainage, as they did not include patients undergoing neoadjuvant therapy, and they solely utilized PES. Additionally, although SEMS are more expensive compared with PES, SEMS appear to be cost eff ective in patients awaiting PD when the greater incidence of cholangitis associated with PES is taken into account ( 7, 8, 18 ) .
Despite support in the literature that SEMS provide faster relief from jaundice and have more durable patency than PES, concerns persist that SEMS result in greater operative and postoperative complications, and create technical diffi culties that may compromise R0 resection, interfere with biliary reconstruction, or prohibit resection altogether. Th ese theoretical complications arise in part from concerns of local infl ammation that SEMS may cause ( 19 ) . Several small studies have shown that SEMS do not increase operative complications in patients who have undergone PD, but no study has investigated the impact on the R0 resection rate or the rates of nontherapeutic laparotomy ( 7 -10,17,20 ) . In our study, we sought to compare the surgical outcomes, including margin status on pathology, and compare the rates of unresectability of a relatively large group of patients undergoing PD with SEMS in place compared with those with PES and NS. Our study was not designed to evaluate the effi cacy of biliary stenting, but to investigate the surgical outcomes of SEMS when in place at the time of PD.
In patients who required endoscopic biliary stents, our study found that placement of a SEMS did not increase overall postoperative complications including more severe (grade 3 -4) complications, biliary or pancreatic anastomotic leak, and 30-day mortality. On the contrary, there was an increase in wound infection in the SEMS group compared with both the NS and PES groups. However, this did not result in any diff erence in the length of stay or severity of adverse events, inferring these infections were managed medically and were without further complications. Th ese fi ndings may be the cause of the increase in overall complications in the SEMS group compared with the NS group in the multivariate model. Th ere was an increase in operative times in the SEMS group, but again this had minimal clinical impact given the lack of diff erence in the length of stay and overall postoperative complications. Moreover, the patients in the SEMS group had signifi cantly more comorbidities, and were more likely to have received preoperative
